Oncogenic activation of tyrosine kinases - PubMed (original) (raw)
Review
Oncogenic activation of tyrosine kinases
G A Rodrigues et al. Curr Opin Genet Dev. 1994 Feb.
Abstract
Tyrosine kinases comprise the largest group of oncoproteins, a fact that underscores the importance of reversible tyrosine phosphorylation in the regulation of essential cellular functions. Oncogenic activation of tyrosine kinases results in the constitutive activation of what is normally a conditionally regulated enzyme activity. Studies of tyrosine kinase oncoproteins, and a comparison with their corresponding proto-oncogene products, have identified important functional and regulatory domains within these proteins, positive and negative regulators of their enzyme activities and signalling cascades that control cell growth and differentiation.
Similar articles
- Oncogenic kinase signalling.
Blume-Jensen P, Hunter T. Blume-Jensen P, et al. Nature. 2001 May 17;411(6835):355-65. doi: 10.1038/35077225. Nature. 2001. PMID: 11357143 Review. - Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones.
Crossthwaite AJ, Valli H, Williams RJ. Crossthwaite AJ, et al. J Neurochem. 2004 Mar;88(5):1127-39. doi: 10.1046/j.1471-4159.2004.02257.x. J Neurochem. 2004. PMID: 15009668 - Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G. Santoro MM, et al. Oncogene. 1998 Aug 13;17(6):741-9. doi: 10.1038/sj.onc.1201994. Oncogene. 1998. PMID: 9715276 - Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
Porter AC, Vaillancourt RR. Porter AC, et al. Oncogene. 1998 Sep 17;17(11 Reviews):1343-52. doi: 10.1038/sj.onc.1202171. Oncogene. 1998. PMID: 9779982 Review.
Cited by
- Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. Abbaspour Babaei M, et al. Drug Des Devel Ther. 2016 Aug 1;10:2443-59. doi: 10.2147/DDDT.S89114. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27536065 Free PMC article. Review. - TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment.
Cabrera N, Díaz-Rodríguez E, Becker E, Martín-Zanca D, Pandiella A. Cabrera N, et al. J Cell Biol. 1996 Feb;132(3):427-36. doi: 10.1083/jcb.132.3.427. J Cell Biol. 1996. PMID: 8636219 Free PMC article. - Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.
Mugiya T, Mothibe M, Khathi A, Ngubane P, Sibiya N. Mugiya T, et al. Front Pharmacol. 2024 Feb 1;15:1355171. doi: 10.3389/fphar.2024.1355171. eCollection 2024. Front Pharmacol. 2024. PMID: 38362147 Free PMC article. Review. - Increased constitutive activity of mitogen-activated protein kinase and renaturable 85 kDa kinase in human-colorectal cancer.
Ostrowski J, Trzeciak L, Kołodziejski J, Bomsztyk K. Ostrowski J, et al. Br J Cancer. 1998 Nov;78(10):1301-6. doi: 10.1038/bjc.1998.675. Br J Cancer. 1998. PMID: 9823970 Free PMC article. - Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.
Pal K, Bandyopadhyay A, Zhou XE, Xu Q, Marciano DP, Brunzelle JS, Yerrum S, Griffin PR, Vande Woude G, Melcher K, Xu HE. Pal K, et al. Structure. 2017 Jun 6;25(6):867-877.e3. doi: 10.1016/j.str.2017.04.015. Epub 2017 May 18. Structure. 2017. PMID: 28528776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources